Literature DB >> 11694096

Animal models of zygomycosis--Absidia, Rhizopus, Rhizomucor, and Cunninghamella.

K Kamei1.   

Abstract

Infections caused by zygomycetes, which have been increasing in recent years, are known for their difficulty of diagnosis and treatment. Because little is known about this fungus and its infection, vigorous research is now in serious demand. As in many other systemic mycoses, animal model studies are essential in the investigation of zygomycosis, particularly for the study of pathogenesis, diagnosis and treatment. Unfortunately, such studies have been limited when compared with those of aspergillosis. To help investigating the disease, here in this review article, the profile of human zygomycosis is briefly described, followed by a review of the heretofore used animal models of zygomycosis. Among clinically important zygomycetes causing human infection, animal models are available for Absidia corymbifera, Rhizopus oryzae, R. microsporus var. rhizopodiformis, Rhizomucor pusillus and Cunninghamella bertholletiae. Mice are the most commonly used animals, but models using guinea pigs and rabbits are also available. Pretreatment of animals with cyclophosphamide, corticosteroid, alloxan or streptozocine is frequently done to create an immunocompromised state. Treatment with desferrioxamine, an iron chelator, is also used to make animal models. In terms of the route of infection, the airborne route is used for pathophysiological studies in pulmonary infection models, but sometimes intravenous injection is preferred, particularly for antifungal drug studies. When pathophysiological analysis is the purpose of the study, the animals must be cautiously examined both histopathologically and mycologically. For the most part, zygomycosis model studies can be performed in a similar manner to those of aspergillosis. However, Aspergillus spp. and zygomycetes are completely different fungi, and researchers should be aware of the specific, critical aspects when handling zygomycosis models, such as homogenization of infected organs and staining of pathological samples.

Entities:  

Mesh:

Year:  2001        PMID: 11694096     DOI: 10.1023/a:1011900630987

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   3.785


  42 in total

1.  Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles.

Authors:  A M Sugar; X P Liu
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B.

Authors:  J Van Cutsem; F Van Gerven; J Fransen; P A Janssen
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

Review 3.  Intracranial complications of mucormycosis: an experimental model and clinical review.

Authors:  V K Anand; G Alemar; J A Griswold
Journal:  Laryngoscope       Date:  1992-06       Impact factor: 3.325

4.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.

Authors:  J R Boelaert; J Van Cutsem; M de Locht; Y J Schneider; R R Crichton
Journal:  Kidney Int       Date:  1994-03       Impact factor: 10.612

Review 6.  Cunninghamella infections: review and report of two cases of Cunninghamella pneumonia in immunocompromised children.

Authors:  A Cohen-Abbo; P M Bozeman; C C Patrick
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

Review 7.  Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine.

Authors:  T Kaneko; F Abe; M Ito; M Hotchi; K Yamada; Y Okada
Journal:  Acta Pathol Jpn       Date:  1991-07

8.  Experimental systemic bovine zygomycosis with reference to pathology and secretion of antigen into urine.

Authors:  H E Jensen; P L Frandsen; H Schønheyder
Journal:  Zentralbl Veterinarmed B       Date:  1993-02

9.  Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.

Authors:  A R Waldorf; N Ruderman; R D Diamond
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

View more
  9 in total

Review 1.  Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.

Authors:  Marisa Z R Gomes; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

2.  Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model.

Authors:  Bianca Schulze; Günter Rambach; Volker U Schwartze; Kerstin Voigt; Katja Schubert; Cornelia Speth; Ilse D Jacobsen
Journal:  Virulence       Date:  2017-08-24       Impact factor: 5.882

3.  Future directions in mucormycosis research.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis; Oliver Lortholary; Oliver Lotholary; Brad Spellberg; Georgios Petrikkos; Emmanuel Roilides; Emmanuel Roillides; Ashraf Ibrahim; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 4.  How I treat mucormycosis.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Blood       Date:  2011-05-26       Impact factor: 22.113

5.  Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.

Authors:  Javier Capilla; Clara Yustes; Emili Mayayo; Belkys Fernández; Montserrat Ortoneda; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 6.  Overview of vertebrate animal models of fungal infection.

Authors:  Tobias M Hohl
Journal:  J Immunol Methods       Date:  2014-04-04       Impact factor: 2.303

Review 7.  Early-diverging fungal phyla: taxonomy, species concept, ecology, distribution, anthropogenic impact, and novel phylogenetic proposals.

Authors:  Kerstin Voigt; Timothy Y James; Paul M Kirk; André L C M de A Santiago; Bruce Waldman; Gareth W Griffith; Minjie Fu; Renate Radek; Jürgen F H Strassert; Christian Wurzbacher; Gustavo Henrique Jerônimo; David R Simmons; Kensuke Seto; Eleni Gentekaki; Vedprakash G Hurdeal; Kevin D Hyde; Thuong T T Nguyen; Hyang Burm Lee
Journal:  Fungal Divers       Date:  2021-09-29       Impact factor: 24.902

8.  Robust Phagocyte Recruitment Controls the Opportunistic Fungal Pathogen Mucor circinelloides in Innate Granulomas In Vivo.

Authors:  Sarah Inglesfield; Aleksandra Jasiulewicz; Matthew Hopwood; James Tyrrell; George Youlden; Maria Mazon-Moya; Owain R Millington; Serge Mostowy; Sara Jabbari; Kerstin Voelz
Journal:  MBio       Date:  2018-03-27       Impact factor: 7.867

Review 9.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.